摘要
HepatitisBvirus（HBV）isasignificantglobalpathogenandefficientcureforHBVpatientsisstillachallenginggoal.Wepreviouslyreportedthatacidicmucopolysaccharidefromstichopusjaponicusselenka（SJAMP）couldinhibitHBsAgandHBeAgexpressioninvitro.However,thepotentialanti-HBVeffectsofSJAMPinvivohavenotyetbeenexplored.Inthisstudy,weshowthatSJAMPexhibitspotentanti-HBVactivityinHBVtransgenicmiceinadose-dependentmanner.Specifically,sixtyHBVtransgenicmaleBALB/cmicewererandomlyselectedtoreceivethetreatmentofPBS,lowdoseSJAMP(30mgkg-1),middledoseSJAMP(40mgkg-1),highdoseSJAMP(50mgkg-1)andIFN(45IUkg-1)for30d.SJAMPtreatmentsuppressedserumHBV-DNA,andliverHBsAgandHBcAglevelsinHBV-transgenicmice.ThepresentstudyhighlightsthepotentialapplicationofSJAMPinHBVtherapy.
出版日期
2016年04月14日（中国期刊网平台首次上网日期，不代表论文的发表时间）
